loadpatents
name:-0.017332077026367
name:-0.011610984802246
name:-0.00049495697021484
Pietrzynski; Grzegorz Patent Filings

Pietrzynski; Grzegorz

Patent Applications and Registrations

Patent applications and USPTO patent grants for Pietrzynski; Grzegorz.The latest application filed is for "cabazitaxel composition".

Company Profile
0.13.17
  • Pietrzynski; Grzegorz - Montreal CA
  • Pietrzynski; Grzegorz - Quebec CA
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Cabazitaxel composition
Grant 9,919,053 - Alakhov , et al. March 20, 2
2018-03-20
Cabazitaxel Composition
App 20150328321 - ALAKHOV; Valery ;   et al.
2015-11-19
Rapamycin composition
Grant 8,912,215 - Pietrzynski , et al. December 16, 2
2014-12-16
Bendamustine cyclopolysaccharide compositions
Grant 8,703,964 - Popek , et al. April 22, 2
2014-04-22
Bendamustine Cyclopolysaccharide Compositions
App 20130190372 - POPEK; Tomasz ;   et al.
2013-07-25
Mixed Poloxamer Excipients
App 20130150311 - Pietrzynski; Grzegorz ;   et al.
2013-06-13
Rapamycin Composition
App 20130150397 - Pietrzynski; Grzegorz ;   et al.
2013-06-13
Bendamustine cyclopolysaccharide compositions
Grant 8,436,032 - Popek , et al. May 7, 2
2013-05-07
Bendamustine anionic-catioinic cyclopolysaccharide compositions
Grant 8,383,663 - Alakhov , et al. February 26, 2
2013-02-26
Doxorubicin formulations for anti-cancer use
Grant 8,148,338 - Klinski , et al. April 3, 2
2012-04-03
Bendamustine Anionic-catioinic Cyclopolysaccharide Compositions
App 20120015995 - Alakhov; Valery ;   et al.
2012-01-19
Cyclopolysaccharide Compositions
App 20110207764 - Alakhov; Valery ;   et al.
2011-08-25
Sn-38 Compositions
App 20110207760 - Alakhov; Valery ;   et al.
2011-08-25
Bendamustine Cyclopolysaccharide Compositions
App 20100216858 - Popek; Tomasz ;   et al.
2010-08-26
Method of treating tumors with azaxanthones
Grant 7,772,255 - Semov , et al. August 10, 2
2010-08-10
Method of Treating Tumors with Azaxanthones
App 20090042923 - Semov; Alexandre ;   et al.
2009-02-12
Doxorubicin formulations for anti-cancer use
App 20070196493 - Klinski; Evgueni ;   et al.
2007-08-23
Method of treating tumors with azaxanthones
App 20070135473 - Semov; Alexandre ;   et al.
2007-06-14
Ligand for vascular endothelial growth factor receptor
Grant 7,112,654 - Tchistiakova , et al. September 26, 2
2006-09-26
Therapeutic compositions and methods for treating diseases that involve angiogenesis
App 20050277575 - Semov, Alexandre ;   et al.
2005-12-15
Ligand for vascular endothelial growth factor receptor
App 20040266694 - Tchistiakova, Lioudmila ;   et al.
2004-12-30
Ligand for vascular endothelial growth factor receptor
Grant 6,733,755 - Tchistiakova , et al. May 11, 2
2004-05-11
Ligand for enhancing oral and CNS delivery of biological agents
Grant 6,696,274 - Tchistiakova , et al. February 24, 2
2004-02-24
Ligand for enhancing oral and CNS delivery of biological agents
App 20020137684 - Tchistiakova, Lioudmila ;   et al.
2002-09-26
Ligand for vascular endothelial growth factor receptor
App 20020058619 - Tchistiakova, Lioudmila ;   et al.
2002-05-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed